Last update 21 Jun 2024
Medroxyprogesterone Acetate
Last update 21 Jun 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms (6α)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dione, 17-Acetoxy-6α-methylprogesterone, 17α-hydroxy-6α-methylprogesterone acetate + [34] |
Target |
Mechanism PR agonists(Progesterone receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (18 Jun 1959), |
RegulationOrphan Drug (US) |
Login to view First Approval Timeline
Structure
Molecular FormulaC24H34O4 |
InChIKeyPSGAAPLEWMOORI-PEINSRQWSA-N |
CAS Registry71-58-9 |
Related
159
Clinical Trials associated with Medroxyprogesterone AcetateComparing the Safety and Efficacy in the Use of Dienogest, Leuprolide Acetate, DMPA and Combined Oral Contraceptive Pills (Microgynon) on Endometriosis Patients After Conservative Surgery
An Open-label,two-arm, Exploratory Randomised Controlled Trial to evaluate the effect of Vardhamana Pippali Rasayana as an add-on therapy in the management of Non-small cell lung cancer - NIL
Endometrial Biopsy in Progestin Contraceptive Users
100 Clinical Results associated with Medroxyprogesterone Acetate
Login to view more data
100 Translational Medicine associated with Medroxyprogesterone Acetate
Login to view more data
100 Patents (Medical) associated with Medroxyprogesterone Acetate
Login to view more data
11,765
Literatures (Medical) associated with Medroxyprogesterone Acetate31 Dec 2024Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
Comparison of resumption of ovulation after cessation of oral contraceptives and medroxyprogesterone acetate in women with polycystic ovary syndrome
Article
Author: Kim, Hoon ; Ku, Seung-Yup ; Han, Soo Jin ; Suh, Chang Suk
OBJECTIVE:
Both oral contraceptive pills (OCPs) and cyclic medroxyprogesterone acetate (MPA) are widely used to control menstrual abnormalities in women with polycystic ovary syndrome (PCOS). We aimed to evaluate the chance of ovulation resumption after cessation of OCPs and MPA in women with PCOS.
METHODS:
A retrospective study was conducted of women with PCOS who were treated with OCPs or cyclic MPA from September 2015 to March 2019. After cessation of medication, ovulation was assessed using basal body temperature and/or measurement of serum progesterone. The odds ratio for ovulation resumption was assessed with multivariable logistic regression. Additionally, doubly robust analysis was performed with inverse-probability-weighted analysis and regression adjustment based on the covariate balancing propensity score to adjust for the effect of covariates on the treatment assignment.
RESULTS:
Among 272 women with PCOS, 136 were prescribed OCPs and 136 were prescribed cyclic MPA. Ovulation resumed in 18.4% of women (n = 25) after cessation of MPA and in 24.3% of women (n = 33) after cessation of OCPs. The odds of ovulation resumption in MPA users were comparable with those in OCP users (adjusted odds ratio (aOR) 1.00, 95% confidence interval (CI) 0.89-1.12). After multiple imputation due to missing values, the results did not change substantially (aOR 0.99, 95% CI 0.89-1.10).
CONCLUSIONS:
Among women with PCOS, MPA users have a similar chance of ovulation resumption as OCP users after cessation of medication. Cyclic MPA can be a good alternative to OCPs in women for whom OCPs are contraindicated or who decline to take OCPs.
01 Mar 2024Steroids
cAMP regulates the progesterone receptor gene expression through the protein kinase A pathway during decidualization in human immortalized endometrial stromal cells
Article
Author: Vázquez-Martínez, Edgar Ricardo ; Romero-Reyes, Jessica ; Cid-Cruz, Yesenia ; León-Juárez, Moisés ; Retis-Resendiz, Alejandra Monserrat ; Camacho-Arroyo, Ignacio ; García-Gómez, Elizabeth ; Velázquez-Hernández, Dora María
Decidualization, a crucial process for successful pregnancy establishment and maintenance, involves endometrial stromal cell differentiation. This process is orchestrated by estradiol (E2), progesterone, and other stimuli that increase intracellular cyclic adenosine monophosphate (cAMP) levels. The intracellular progesterone receptor (PR), encoded by the PGR gene, has a key role in decidualization. This study aimed to understand the role of sex steroids and cAMP in regulating PGR expression during the in vitro decidualization of the human immortalized endometrial stromal cell line, T-HESC. We subjected the cells to individual and combined treatments of E2, medroxyprogesterone (MPA), and cAMP. Additionally, we treated cells with PR and estrogen receptor antagonists and a protein kinase A (PKA) inhibitor. We evaluated the expression of PGR isoforms and decidualization-associated genes by RT-qPCR. Our findings revealed that cAMP induced PGR-B and PGR-AB expression by activating the PKA signaling pathway, while MPA downregulated their expression through the PR. Furthermore, downstream genes involved in decidualization, such as those coding for prolactin (PRL), insulin-like growth factor-binding protein-1 (IGFBP1), and Dickkopf-1 (DKK1), exhibited positive regulation via the cAMP-PKA pathway. Remarkably, MPA-activated PR signaling induced the expression of IGFBP1 and DKK1 but inhibited that of PRL. In conclusion, we have demonstrated that the PKA signaling pathway induces PGR gene expression during in vitro decidualization of the T-HESC human endometrial stromal cell line. This study has unraveled some of the intricate regulatory mechanisms governing PGR expression during this fundamental process for implantation and pregnancy maintenance.
01 Mar 2024Reproductive biomedicine online
Corrigendum to ‘Medroxyprogesterone acetate: an alternative to GnRH-antagonist in oocyte vitrification for social fertility preservation and preimplantation genetic testing for aneuploidy’ Reproductive Biomedicine Online. 2023 Aug;47(2):103222
Author: Bosch, E ; Cobo, A ; Vidal, C ; Requena, A ; Giles, J ; Cruz, M ; Remohi, J
7
News (Medical) associated with Medroxyprogesterone Acetate23 May 2024
16 Nov 2023
04 Jul 2023
Drug ApprovalBiosimilarPatent ExpirationPatent Infringement
100 Deals associated with Medroxyprogesterone Acetate
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Suppression of ovulation | JP | 11 Mar 2022 | |
| Pain | US | 04 Dec 2020 | |
| Contraception | US | 17 Dec 2004 | |
| Pregnancy | US | 29 Oct 1992 | |
| Breast Cancer | CN | 01 Jan 1982 | |
| Endometrial Carcinoma | CN | 01 Jan 1982 | |
| Prostatic Cancer | CN | 01 Jan 1982 | |
| Renal Cell Carcinoma | CN | 01 Jan 1982 | |
| Abortion, Habitual | JP | 25 Jan 1963 | |
| Abortion, Threatened | JP | 25 Jan 1963 | |
| Hypomenorrhea | JP | 25 Jan 1963 | |
| Infertility | JP | 25 Jan 1963 | |
| Menorrhagia | JP | 25 Jan 1963 | |
| Amenorrhea | US | 18 Jun 1959 | |
| Endometrial Hyperplasia | US | 18 Jun 1959 | |
| Metrorrhagia | US | 18 Jun 1959 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Dermatitis, Atopic | Phase 3 | CN | 11 Dec 2019 | |
| Eczema | Phase 3 | CN | 11 Dec 2019 | |
| Neurodermatitis | Phase 3 | CN | 11 Dec 2019 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | - | 615 | Depot medroxyprogesterone acetate (DMPA-IM) | wimhhpnccp(wqhidjwinw) = otohyfvadf tebxjkexdm (smuagsohqx ) | - | 08 Mar 2024 | |
wimhhpnccp(wqhidjwinw) = fnlldbnaem tebxjkexdm (smuagsohqx ) | |||||||
Not Applicable | 4,062 | Depot medroxyprogesterone acetate (DMPA-IM) | rpeotpkaci(kxftrfajso) = emfotqgaor piuapedzvc (zmxnadkczd ) | - | 10 Sep 2022 | ||
Levonorgestrel (LNG) implant | rpeotpkaci(kxftrfajso) = fmpnnnrvue piuapedzvc (zmxnadkczd ) | ||||||
Not Applicable | 17 | Placebo (Placebo) | qnzkluehzk(wosmtshugn) = sjttwzjfdv eastuakkuz (qmladjoxyr, pqtjxpbcyq - kvinbhqpay) View more | - | 10 Jan 2022 | ||
(GnRH Agonist) | qnzkluehzk(wosmtshugn) = bzarqiyaxo eastuakkuz (qmladjoxyr, eohmrqwtyf - udchbutpwk) View more | ||||||
Not Applicable | - | 401 | yliwsbulya(ukshcmnfih) = citokzdjed xuszinujux (ahaohthzfv ) | - | 01 Jan 2022 | ||
Copper Intrauterine Device | yliwsbulya(ukshcmnfih) = ayyjlspooh xuszinujux (ahaohthzfv ) | ||||||
Not Applicable | 4,062 | gdyoetxukl(bjoriagiam) = ixmsmanmny kxwazwxphd (llsnnldkxn ) | - | 15 Dec 2021 | |||
gdyoetxukl(bjoriagiam) = gnusevtvti kxwazwxphd (llsnnldkxn ) | |||||||
Not Applicable | 458 | dbqtmfyduf(aavfilycdx) = dcrhrtlyrk xlhkjlqnuv (tymwasvbwa ) View more | - | 01 Jan 2021 | |||
Copper IUD | bodsivolqi(mmqwhrpzau) = yrggdydgcm hharcawhtp (ftakzlfbbx ) | ||||||
Phase 2 | 96 | (Estradiol/Medroxyprogesterone Acetate) | ejhvvahpjz(nhogfmvewi) = wbgdcbetcl rzpaeutlzi (xdcqufursy, wbrtzslghu - xptizueden) View more | - | 07 Dec 2020 | ||
Soy Placebo (Placebo) | ejhvvahpjz(nhogfmvewi) = ozezzsxsvq rzpaeutlzi (xdcqufursy, ffmbbrpsmc - fvpqgsqfqh) View more | ||||||
Not Applicable | - | - | Provera users with weight gain (> 5% from baseline) | znpwgzaaip(axsutpowsb) = vkxtloyzdn lxapilzsur (cjuaofexqv ) View more | - | 04 Nov 2020 | |
Provera users without weight gain | znpwgzaaip(axsutpowsb) = xlayofuhnd lxapilzsur (cjuaofexqv ) | ||||||
Not Applicable | - | 731 | (Young women (18-24 years)) | funzgbbity(ykptgrleqb) = xbyyigwsrn ocunemacuy (jkcwcctjvl ) View more | - | 07 May 2020 | |
(Older women (≥25 years)) | funzgbbity(ykptgrleqb) = lhzwkafgjf ocunemacuy (jkcwcctjvl ) View more | ||||||
Not Applicable | - | ntzkuvoiju(bergsjajhx) = nlzztltojx ytliiymltw (gjhcrsezfz ) | - | 01 Jan 2020 | |||
ntzkuvoiju(bergsjajhx) = caeyrxruky ytliiymltw (gjhcrsezfz ) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free